HC Wainwright Begins Coverage on Omeros (NASDAQ:OMER)

HC Wainwright started coverage on shares of Omeros (NASDAQ:OMER - Free Report) in a research report released on Tuesday, MarketBeat Ratings reports. The firm issued a buy rating and a $9.00 target price on the biopharmaceutical company's stock.

Several other research analysts have also weighed in on OMER. Wall Street Zen lowered shares of Omeros from a "hold" rating to a "sell" rating in a report on Friday. D. Boral Capital reiterated a "buy" rating and issued a $36.00 price target on shares of Omeros in a research note on Tuesday, May 13th. Finally, Needham & Company LLC restated a "hold" rating on shares of Omeros in a research note on Friday, May 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $18.00.

Omeros Stock Performance

Shares of NASDAQ OMER traded up $0.11 during midday trading on Tuesday, reaching $3.88. 1,246,306 shares of the company's stock were exchanged, compared to its average volume of 685,858. Omeros has a 52-week low of $2.97 and a 52-week high of $13.60. The business's fifty day moving average price is $5.37 and its two-hundred day moving average price is $7.91. The stock has a market capitalization of $227.34 million, a PE ratio of -1.68 and a beta of 2.20.

Omeros (NASDAQ:OMER - Get Free Report) last announced its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05). Analysts predict that Omeros will post -3.09 earnings per share for the current fiscal year.

Institutional Trading of Omeros

A number of institutional investors and hedge funds have recently made changes to their positions in OMER. Vanguard Group Inc. increased its holdings in shares of Omeros by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company's stock worth $26,610,000 after acquiring an additional 95,599 shares during the period. Nomura Holdings Inc. boosted its position in shares of Omeros by 136.2% during the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company's stock valued at $7,383,000 after purchasing an additional 430,932 shares in the last quarter. Two Sigma Investments LP increased its holdings in shares of Omeros by 8.8% in the fourth quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company's stock valued at $1,610,000 after buying an additional 13,201 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Omeros by 2.2% during the first quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company's stock valued at $1,242,000 after purchasing an additional 3,321 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Omeros in the fourth quarter worth about $1,488,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.